Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective

Autor: Bouwmeester, R.N., Duineveld, C., Wijnsma, K.L., Bemelman, F.J., Heijden, J.W. van der, Wijk, J.A.E. van, Bouts, A.H.M., Wetering, J. van de, Dorresteijn, E., Berger, S.P., Gracchi, V., Zuilen, A.D. van, Keijzer-Veen, M.G., Vries, A.P.J. de, Rooij, R.W.G. van, Engels, F.A.P.T., Altena, W., Wildt, R. de, Kempen, E. van, Adang, E.M., Avest, M. ter, Heine, R. ter, Volokhina, E.B., Heuvel, L.P.W.J. van den, Wetzels, J.F.M., Kar, N.C.A.J. van de

Publikováno v: Bouwmeester, R N, Duineveld, C, Wijnsma, K L, Bemelman, F J, van der Heijden, J W, van Wijk, J A E, Bouts, A H M, van de Wetering, J, Dorresteijn, E, Berger, S P, Gracchi, V, van Zuilen, A D, Keijzer-Veen, M G, de Vries, A P J, van Rooij, R W G, Engels, F A P T, Altena, W, de Wildt, R, van Kempen, E, Adang, E M, ter Avest, M, ter Heine, R, Volokhina, E B, van den Heuvel, L P W J, Wetzels, J F M & van de Kar, N C A J 2022, ' Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective : Results of the CUREiHUS Study ', Kidney International Reports, vol. 8, no. 1, pp. 91-102 . https://doi.org/10.1016/j.ekir.2022.10.013
Kidney International Reports, 8(1), 91-102. Elsevier Inc.
Kidney International Reports, 8, 1, pp. 91-102
Kidney International Reports, 8(1), 91-102. Elsevier Science
Kidney International Reports, 8(1), 91-102. ELSEVIER SCIENCE INC
Kidney International Reports, 8, 91-102
Kidney International Reports. Elsevier Inc.

Introduction: The introduction of eculizumab has improved the outcome in patients with atypical hemo-lytic uremic syndrome (aHUS). The optimal treatment strategy is debated. Here, we report the results of the CUREiHUS study, a 4-year prospective, obs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da7d699e40d5937c24775971a41a47d3
https://hdl.handle.net/1887/3563249

Proteinuria and Exposure to Eculizumab in Atypical Hemolytic Uremic Syndrome

Autor: Avest, M. ter, Steenbreker, H., Bouwmeester, R.N., Duineveld, C., Wijnsma, K.L., Heuvel, L.P.W.J. van den, Langemeijer, S.M.C., Wetzels, J.F.M., Kar, N.C.A.J. van de, Heine, R. ter

Publikováno v: Clinical Journal of the American Society of Nephrology, 18, 6, pp. 759-766
Clinical Journal of the American Society of Nephrology, 18, 759-766

Item does not contain fulltext BACKGROUND: Eculizumab is a monoclonal antibody for the treatment of atypical hemolytic uremic syndrome (aHUS). Kidney damage, a common condition in patients with aHUS, may result in proteinuria. Because proteinuria may

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1eef95f3b8662398bbb229d9db0747e4
https://repository.ubn.ru.nl/handle/2066/293811

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.